目的 探究麝香保心丸聯(lián)合替格瑞洛片治療冠心病心絞痛的臨床療效。方法 選擇2019年11月—2021年2月在濟源市人民醫(yī)院就診治療的102例冠心病心絞痛患者，按照入院先后順序?qū)⑺谢颊叻譃閷φ战M和治療組，每組各51例。對照組口服替格瑞洛片，90 mg/次，2次/d。治療組在對照組的基礎(chǔ)上口服麝香保心丸，45 mg/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組患者的臨床療效、心電圖療效，比較兩組治療前后的心絞痛發(fā)作狀況、心功能指標、血清炎性因子。結(jié)果 治療后，治療組患者的心絞痛療效、心電圖療效總有效率均高于對照組，組間比較有差異（P＜0.05）。治療后，兩組患者的發(fā)作頻率、發(fā)作持續(xù)時間均顯著降低，同組比較有差異（P＜0.05）；并且治療組的發(fā)作頻率、發(fā)作持續(xù)時間較對照組改善明顯，組間比較有差異（P＜0.05）。治療后，兩組患者的左心室射血分數(shù)（LVEF）顯著降低，心輸出量（CO）、每搏輸出量（SV）顯著升高，同組比較有差異（P＜0.05）；并且治療組患者的LVEF顯著低于對照組，CO、SV顯著高于對照組，組間比較有差異（P＜0.05）。治療后，兩組患者的白細胞介素-6（IL-6）、同型半胱氨酸（Hcy）、缺血修飾白蛋白（IMA）水平均顯著降低，同組比較有差異（P＜0.05）；并且治療組患者IL-6、Hcy、IMA水平均明顯低于對照組，組間比較有顯著差異（P＜0.05）。結(jié)論 麝香保心丸聯(lián)合替格瑞洛片治療冠心病心絞痛具有較好的臨床療效，可改善患者臨床癥狀，提高患者的心功能，降低炎性反應(yīng)，安全性較好，具有一定臨床應(yīng)用價值。

Objective To explore the clinical study of Shexiang Baoxin Pills combined with Ticagrelor Tablets in treatment of angina pectoris of coronary heart disease.Methods Patients (102 cases) with angina pectoris of coronary heart disease in Jiyuan Shi People's Hospital from November 2019 to February 2021 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were po administered with Shexiang Baoxin Pills on the basis of the control group, 45 mg/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies of angina pectoris and ECG were evaluated, and the attack status of angina pectoris, cardiac functions, and serum inflammatory factors in two groups were compared.Results After treatment, the total effective rates of angina pectoris and ECG in the treatment group were higher than those in the control group, and there was a difference between the groups (P < 0.05). After treatment, the attack frequency and duration of two groups were significantly lower than those of the control group (P < 0.05), and the attack frequency and duration of the treatment group were significantly improved than those of the control group (P < 0.05). After treatment, the LVEF of two groups were significantly decreased, but the CO and SV of two groups were significantly increased, and there was a significant difference in the same group (P < 0.05). The LVEF of the treatment group was significantly lower than that of the control group, but the CO and SV of the treatment group were significantly higher than those of the control group (P < 0.05). After treatment, the levels of IL-6, Hcy, and IMA in two groups were significantly decreased, and there was a significant difference in the same group (P < 0.05). And the levels of IL-6, Hcy, and IMA in the treatment group were significantly lower than those in the control group (P < 0.05).Conclusion Shexiang Baoxin Pills combined with Ticagrelor Tablets has curative effect in treatment of angina pectoris of coronary heart disease, can improve patients' clinical symptoms, improve patients' cardiac function, and reduce inflammatory reaction, with good safety, which has a certain clinical application value.

R972

國家自然科學(xué)基金面上項目（81373610）；濟源市科技攻關(guān)項目（17023013）